Tags

Type your tag names separated by a space and hit enter

Effect of antioxidant supplementation on surrogate markers of fibrosis in chronic pancreatitis: a randomized, placebo-controlled trial.
Pancreas. 2013 May; 42(4):589-95.P

Abstract

OBJECTIVES

This study aimed to determine the effect of antioxidant (AO) supplementation on surrogate markers of fibrosis in patients with chronic pancreatitis (CP).

METHODS

In a randomized, placebo (PL)-controlled trial, patients with CP were randomized to groups that were given PL or AO for 3 months. Outcome measures were change in serum levels of transforming growth factor β1 and platelet-derived growth factor AA (PDGF-AA) (primary outcome) as well as blood markers of oxidative stress (thiobarbituric acid-reactive substances) and AO status (ferric-reducing ability of plasma) (secondary outcome). Pain relief and analgesic requirement was also recorded.

RESULTS

Patients (n = 61; mean [SD] age, 35.2 [10.0]; male patients, 43) were assigned to AO (n = 31) and PL (n = 30) groups. The median (range) percent reduction from baseline to 3 months in levels of PDGF-AA (17.1% [-25.3% to 88.7%] vs 2.8% [-243.1% to 30.2%]; P = 0.001), transforming growth factor β1 (P = 0.573), and thiobarbituric acid-reactive substances (P = 0.207) as well as percent increment from baseline to 3 months in ferric-reducing ability of plasma (P = 0.003) were higher in the AO group compared with the PL group. Proportion of patients who had both reduced PDGF-AA and reduced pain was greater in AO as compared with PL group (17/31 vs 9/30, P = 0.05)

CONCLUSIONS

Reduction in markers of fibrosis (PDGF-AA) translated into clinical outcome (reduction in pain and analgesic requirements) in those supplemented with AOs in CP (trial registration, CTRI/2011/05/001747).

Authors+Show Affiliations

Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23531998

Citation

Dhingra, Rajan, et al. "Effect of Antioxidant Supplementation On Surrogate Markers of Fibrosis in Chronic Pancreatitis: a Randomized, Placebo-controlled Trial." Pancreas, vol. 42, no. 4, 2013, pp. 589-95.
Dhingra R, Singh N, Sachdev V, et al. Effect of antioxidant supplementation on surrogate markers of fibrosis in chronic pancreatitis: a randomized, placebo-controlled trial. Pancreas. 2013;42(4):589-95.
Dhingra, R., Singh, N., Sachdev, V., Upadhyay, A. D., & Saraya, A. (2013). Effect of antioxidant supplementation on surrogate markers of fibrosis in chronic pancreatitis: a randomized, placebo-controlled trial. Pancreas, 42(4), 589-95. https://doi.org/10.1097/MPA.0b013e31826dc2d7
Dhingra R, et al. Effect of Antioxidant Supplementation On Surrogate Markers of Fibrosis in Chronic Pancreatitis: a Randomized, Placebo-controlled Trial. Pancreas. 2013;42(4):589-95. PubMed PMID: 23531998.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of antioxidant supplementation on surrogate markers of fibrosis in chronic pancreatitis: a randomized, placebo-controlled trial. AU - Dhingra,Rajan, AU - Singh,Namrata, AU - Sachdev,Vikas, AU - Upadhyay,Ashish Datt, AU - Saraya,Anoop, PY - 2013/3/28/entrez PY - 2013/3/28/pubmed PY - 2013/12/16/medline SP - 589 EP - 95 JF - Pancreas JO - Pancreas VL - 42 IS - 4 N2 - OBJECTIVES: This study aimed to determine the effect of antioxidant (AO) supplementation on surrogate markers of fibrosis in patients with chronic pancreatitis (CP). METHODS: In a randomized, placebo (PL)-controlled trial, patients with CP were randomized to groups that were given PL or AO for 3 months. Outcome measures were change in serum levels of transforming growth factor β1 and platelet-derived growth factor AA (PDGF-AA) (primary outcome) as well as blood markers of oxidative stress (thiobarbituric acid-reactive substances) and AO status (ferric-reducing ability of plasma) (secondary outcome). Pain relief and analgesic requirement was also recorded. RESULTS: Patients (n = 61; mean [SD] age, 35.2 [10.0]; male patients, 43) were assigned to AO (n = 31) and PL (n = 30) groups. The median (range) percent reduction from baseline to 3 months in levels of PDGF-AA (17.1% [-25.3% to 88.7%] vs 2.8% [-243.1% to 30.2%]; P = 0.001), transforming growth factor β1 (P = 0.573), and thiobarbituric acid-reactive substances (P = 0.207) as well as percent increment from baseline to 3 months in ferric-reducing ability of plasma (P = 0.003) were higher in the AO group compared with the PL group. Proportion of patients who had both reduced PDGF-AA and reduced pain was greater in AO as compared with PL group (17/31 vs 9/30, P = 0.05) CONCLUSIONS: Reduction in markers of fibrosis (PDGF-AA) translated into clinical outcome (reduction in pain and analgesic requirements) in those supplemented with AOs in CP (trial registration, CTRI/2011/05/001747). SN - 1536-4828 UR - https://www.unboundmedicine.com/medline/citation/23531998/Effect_of_antioxidant_supplementation_on_surrogate_markers_of_fibrosis_in_chronic_pancreatitis:_a_randomized_placebo_controlled_trial_ L2 - http://dx.doi.org/10.1097/MPA.0b013e31826dc2d7 DB - PRIME DP - Unbound Medicine ER -